Gossamer Bio (NASDAQ:GOSS) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $6.00 price objective on the stock. Gossamer Bio Trading Down 3.5 % GOSS opened at $0.86 on Tuesday. Gossamer Bio has a one year low of […]

Leave a Reply

Your email address will not be published.

Previous post ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of “Hold” by Analysts
Next post Shake Shack (NYSE:SHAK) Earns Hold Rating from Analysts at HSBC